166 related articles for article (PubMed ID: 8173956)
1. Differential modulation of angiotensin II and hypertonic saline-induced drinking by opioid receptor subtype antagonists in rats.
Ruegg H; Hahn B; Koch JE; Bodnar RJ
Brain Res; 1994 Jan; 635(1-2):203-10. PubMed ID: 8173956
[TBL] [Abstract][Full Text] [Related]
2. Central opioid receptor subtype mediation of isoproterenol-induced drinking in rats.
Glass MJ; Hahn B; Joseph A; Bodnar RJ
Brain Res; 1994 Sep; 657(1-2):310-4. PubMed ID: 7820634
[TBL] [Abstract][Full Text] [Related]
3. Central opioid receptor subtype antagonists differentially reduce intake of saccharin and maltose dextrin solutions in rats.
Beczkowska IW; Koch JE; Bostock ME; Leibowitz SF; Bodnar RJ
Brain Res; 1993 Aug; 618(2):261-70. PubMed ID: 8397050
[TBL] [Abstract][Full Text] [Related]
4. Analysis of central opioid receptor subtype antagonism of hypotonic and hypertonic saline intake in water-deprived rats.
Bodnar RJ; Glass MJ; Koch JE
Brain Res Bull; 1995; 36(3):293-300. PubMed ID: 7697383
[TBL] [Abstract][Full Text] [Related]
5. Different central opioid receptor subtype antagonists modify maltose dextrin and deprivation-induced water intake in sham feeding and sham drinking rats.
Leventhal L; Bodnar RJ
Brain Res; 1996 Nov; 741(1-2):300-8. PubMed ID: 9001736
[TBL] [Abstract][Full Text] [Related]
6. Central opioid receptor subtype antagonists differentially alter sucrose and deprivation-induced water intake in rats.
Beczkowska IW; Bowen WD; Bodnar RJ
Brain Res; 1992 Sep; 589(2):291-301. PubMed ID: 1327413
[TBL] [Abstract][Full Text] [Related]
7. Involvement of mu1 and mu2 opioid receptor subtypes in tail-pinch feeding in rats.
Koch JE; Bodnar RJ
Physiol Behav; 1993 Mar; 53(3):603-5. PubMed ID: 8383858
[TBL] [Abstract][Full Text] [Related]
8. Ingestive behavior following central [D-Ala2, Leu5, Cys6]-enkephalin (DALCE), a short-acting agonist and long-acting antagonist at the delta opioid receptor.
Arjune D; Bowen WD; Bodnar RJ
Pharmacol Biochem Behav; 1991 Jun; 39(2):429-36. PubMed ID: 1658817
[TBL] [Abstract][Full Text] [Related]
9. Selective actions of central mu and kappa opioid antagonists upon sucrose intake in sham-fed rats.
Leventhal L; Kirkham TC; Cole JL; Bodnar RJ
Brain Res; 1995 Jul; 685(1-2):205-10. PubMed ID: 7583248
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of opioid receptor subtype antagonist effects in the ventral tegmental area upon food intake under deprivation, glucoprivic and palatable conditions.
Ragnauth A; Ruegg H; Bodnar RJ
Brain Res; 1997 Aug; 767(1):8-16. PubMed ID: 9365010
[TBL] [Abstract][Full Text] [Related]
11. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes.
Jiang Q; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1069-75. PubMed ID: 1646319
[TBL] [Abstract][Full Text] [Related]
12. Selective alterations in macronutrient intake of food-deprived or glucoprivic rats by centrally-administered opioid receptor subtype antagonists in rats.
Koch JE; Bodnar RJ
Brain Res; 1994 Sep; 657(1-2):191-201. PubMed ID: 7820618
[TBL] [Abstract][Full Text] [Related]
13. Delta-opioid receptor antagonists attenuate motor activity induced by amphetamine but not cocaine.
Jones DN; Bowen WD; Portoghese PS; Holtzman SG
Eur J Pharmacol; 1993 Nov; 249(2):167-77. PubMed ID: 8287898
[TBL] [Abstract][Full Text] [Related]
14. General, mu and kappa opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions.
Bodnar RJ; Glass MJ; Ragnauth A; Cooper ML
Brain Res; 1995 Nov; 700(1-2):205-12. PubMed ID: 8624711
[TBL] [Abstract][Full Text] [Related]
15. General, kappa, delta and mu opioid receptor antagonists mediate feeding elicited by the GABA-B agonist baclofen in the ventral tegmental area and nucleus accumbens shell in rats: reciprocal and regional interactions.
Miner P; Shimonova L; Khaimov A; Borukhova Y; Ilyayeva E; Ranaldi R; Bodnar RJ
Brain Res; 2012 Mar; 1443():34-51. PubMed ID: 22305145
[TBL] [Abstract][Full Text] [Related]
16. Reduction by central beta-funaltrexamine of food intake in rats under freely-feeding, deprivation and glucoprivic conditions.
Arjune D; Standifer KM; Pasternak GW; Bodnar RJ
Brain Res; 1990 Dec; 535(1):101-9. PubMed ID: 1963340
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment of rats with the irreversible mu-receptor antagonist, beta-FNA, fails to prevent naltrexone-induced upregulation of mu-opioid receptors.
Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
Neuropharmacology; 1990 Sep; 29(9):805-10. PubMed ID: 1963479
[TBL] [Abstract][Full Text] [Related]
18. Opioid agonist and antagonist antinociceptive properties of [D-Ala2,Leu5,Cys6]enkephalin: selective actions at the deltanoncomplexed site.
Qi JA; Bowen WD; Mosberg HI; Rothman RB; Porreca F
J Pharmacol Exp Ther; 1990 Nov; 255(2):636-41. PubMed ID: 2173752
[TBL] [Abstract][Full Text] [Related]
19. Reductions in body weight following chronic central opioid receptor subtype antagonists during development of dietary obesity in rats.
Cole JL; Leventhal L; Pasternak GW; Bowen WD; Bodnar RJ
Brain Res; 1995 Apr; 678(1-2):168-76. PubMed ID: 7620885
[TBL] [Abstract][Full Text] [Related]
20. The effects of highly selective opioid receptor antagonists on the release of arginine vasotocin induced by hyperosmotic stimulation and angiotensin II injection.
Sasaki T; Arakawa K; Shimada K; Saito N
Gen Comp Endocrinol; 2000 Jun; 118(3):365-72. PubMed ID: 10843787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
